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Abstract
Background: RIFAQUIN was a tuberculosis chemotherapy trial in southern Africa including regimens with high-
dose rifapentine with moxifloxacin. Here, the application of whole-genome sequencing (WGS) is evaluated within
RIFAQUIN for identifying new infections in treated patients as either relapses or reinfections. WGS is further
compared with mycobacterial interspersed repetitive units-variable number tandem repeats (MIRU-VNTR) typing.
This is the first report of WGS being used to evaluate new infections in a completed clinical trial for which all
treatment and epidemiological data are available for analysis.
Methods: DNA from 36 paired samples of Mycobacterium tuberculosis cultured from patients before and after
treatment was typed using 24-loci MIRU-VNTR, in silico spoligotyping and WGS. Following WGS, the sequences
were mapped against the reference strain H37Rv, the single-nucleotide polymorphism (SNP) differences between
pairs were identified, and a phylogenetic reconstruction was performed.
Results: WGS indicated that 32 of the paired samples had a very low number of SNP differences (0–5; likely relapses).
One pair had an intermediate number of SNP differences, and was likely the result of a mixed infection with a pre-
treatment minor genotype that was highly related to the post-treatment genotype; this was reclassified as a relapse, in
contrast to the MIRU-VNTR result. The remaining three pairs had very high SNP differences (>750; likely reinfections).
Conclusions: WGS and MIRU-VNTR both similarly differentiated relapses and reinfections, but WGS provided significant
extra information. The low proportion of reinfections seen suggests that in standard chemotherapy trials with up to
24 months of follow-up, typing the strains brings little benefit to an analysis of the trial outcome in terms of differentiating
relapse and reinfection. However, there is a benefit to using WGS as compared to MIRU-VNTR in terms of the additional
genotype information obtained, in particular for defining the presence of mixed infections and the potential to identify
known and novel drug-resistance markers.
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Background
Evaluations of drug trials for tuberculosis (TB) are
complicated by the fact that a recurrence of disease can ei-
ther be due to endogenous relapse of disease or to subse-
quent exogenous infection with a new strain (reinfection).
Historically, during the major TB chemotherapy trials of
the 1960s to 1980s (reviewed by Fox et al. [1]), it was not
possible to differentiate isolates, and all new infections that
occurred after the trial conclusion were labelled as relapses.
From the 1980s, a series of genomic-based methods
for typing strains of Mycobacterium tuberculosis were
developed, in particular IS6110 restriction fragment
length polymorphism (RFLP), spoligotyping and myco-
bacterial interspersed repetitive units-variable number
tandem repeats (MIRU-VNTR) typing [2–4]. Some trials
therefore began to use molecular methods to differenti-
ate relapses from reinfections. This was initially through
IS6110 RFLP typing [5–7] and then through MIRU-
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VNTR typing [8], while other trials continued without
any differentiation [9].
MIRU-VNTR became the favoured typing approach
because it combined reasonable discrimination with a
readout that could both be easily measured and be
described in a digital form [3]. More recently, whole-
genome sequencing (WGS) has enabled the identification
of single-nucleotide polymorphism (SNP) differences, thus
leading to far greater discrimination in TB epidemiological
studies [10–13].
Two groups have recently used WGS to evaluate
paired samples, comparing SNP differences between the
original infections and new infections following treat-
ment [14, 15]. The study by Bryant et al. [14] was based
on an ongoing clinical trial [16] that was being carried
out in sub-Saharan Africa, south and east Asia, and cen-
tral America. Of the 36 paired samples, 33 were found
to be highly similar (≤6 SNPs; classed as relapses) and
three were highly divergent (≥1306 SNPs; classed as
reinfections).
The report by Guerra-Assunção et al. [15] was not based
on a clinical trial, but was taken from the Karonga Preven-
tion Study, a long-term population-based programme in
Malawi. In this programme, 60 paired samples collected
over a 15-year time period were sequenced, and while the
authors also found a clear division in SNP numbers be-
tween relapses and reinfections, it was not as marked as in
the Bryant study. Thus, they classed 46 samples with 0–8
SNP differences as relapses, and 14 with >100 SNP differ-
ences as reinfections.
In this study, we performed WGS and analysed SNPs
to compare pre- and post-treatment isolates from the
completed RIFAQUIN clinical trial [17], a study evaluat-
ing high-dose rifapentine with moxifloxacin, carried out
in sub-Saharan Africa. Successful sequencing was carried
out on 36 pairs of samples of M. tuberculosis recovered
before treatment and from those patients showing posi-
tive cultures at 6 months, and results were compared
with MIRU-VNTR data. Our results agree with the gen-
eral findings from the two studies referred to above, in
that the overwhelming majority of secondary cases were
classified as relapses. Importantly, WGS was further able
to monitor possible epidemiological connections and
sample errors during the trial, which were not detected
using MIRU-VNTR. Given the added benefit of WGS in
this context, we suggest that WGS should be routinely
used as the method of choice in such trials.
Methods
RIFAQUIN trial
The RIFAQUIN chemotherapy trial, in collaboration
with six institutions in southern Africa, has been previ-
ously described [17]. Between August 2008 and August
2011, patients with newly diagnosed smear-positive
drug-sensitive TB were randomly assigned to one of the
following:
Control regimen: 2 months of daily ethambutol,
isoniazid, rifampicin and pyrazinamide followed by
4 months of daily isoniazid and rifampicin;
4-month regimen: Isoniazid replaced by moxifloxacin
daily for 2 months followed by 2 months of twice-weekly
moxifloxacin and 900 mg rifapentine; or
6-month regimen: Isoniazid replaced by moxifloxacin
daily for 2 months followed by 4 months of once-weekly
moxifloxacin and 1200 mg rifapentine.
Sputum was examined by microscopy and culture at
regular intervals for treatment failure or relapse. Patients
had up to 18 months of follow-up post randomisation,
with the patients recruited last having 12 months of
follow-up post-randomisation. Samples from patients
with two or more consecutive M. tuberculosis-positive
cultures after 6 months (or at the end of treatment) were
selected for WGS.
MIRU-VNTR determination and assignment
The 24-loci MIRU-VNTR typing of these isolates was
previously described [17]. Briefly, a 10 μL loop was used
to pick up a sample of M. tuberculosis colonies by
sweeping across growth on a Lowenstein–Jenson (LJ)
slope. Bacteria were heat-killed and DNA extraction
performed using lysozyme and proteinase K digestion
followed by phenol-chloroform extraction and ethanol
precipitation [18]. The 24 MIRU-VNTR loci were ampli-
fied in eight labelled multiplex PCR reactions, and the
amplicons sized, with MapMarker 1000 standard (BioVen-
tures, Murfreesboro, TN, USAs), by capillary electrophor-
esis on the sequencer (3130 Genetic Analyzer, Applied
Biosystems, Waltham, MA, USA). Analysis was carried
out using the GeneMapper software (Applied Biosys-
tems, Waltham, MA, USA), which assigns alleles based on
the customised bin-sets (fragment sizes and dyes) used to
define each allele. For some samples there was variable
coverage across the MIRU-VNTR loci using the sequen-
cer, so, where possible, any missing loci were confirmed
by single-plex PCR with products sized by standard agar-
ose gel electrophoresis. Where possible, paired samples
(pre- and post-treatment) from a given patient were run
in parallel.
Whole-genome sequencing
For the WGS, 50 μL, containing at least 250 ng, of genomic
DNA from each sample was sheared using the Covaris
E220 for a target size of 200 bp (Peak Incident Power: 175;
duty factor: 10%; cycle/burst: 200; temperature: <8 °C; time:
120 s). Libraries were prepared from sheared DNA using
the NEB DNA Ultra kit in accordance with standard proto-
col (New England Biolabs, Hitchin, UK). The NEB adapters
were substituted for the set described by Kozarewa and
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Turner [19]. Libraries were quantified using the Qubit High
Sensitivity DNA assay and pooled equimolarly (Invitrogen,
UK). The pools were subjected to paired-end sequencing
carried out on a single lane of the Illumina HiSeq 2500 (v3
chemistry, read length 100 bp). Samples which produced a
low yield were re-pooled and sequenced on a single MiSeq
run (v2 chemistry, read length 250 bp).
Sequence analyses
Sequence reads were mapped to the H37Rv reference
genome (RefSeq accession: NC_000962) using bwa mem
v0.7.3a-r367 [20], alignments were sorted, and duplicates
were removed with samtools v0.1.19 [21]. Site statistics
were generated using samtools mpileup and variant sites
were filtered based on the following criteria: mapping
quality above 30, site quality score above 30, at least four
reads covering each site with at least two reads mapping
to each strand, at least 75% of reads supporting site
(DP4) and an allelic frequency of 1. Sites that failed these
criteria in any isolate were removed from the analysis.
Phylogenetic reconstruction was performed using
RAxML v8.2.3 [22] with a General Time Reversible
(GTR) model of nucleotide substitution and a Gamma
model of rate heterogeneity; branch support values were
determined using 1000 bootstrap replicates. Relapse or
reinfection calls were made by applying the above filter-
ing criteria to the individual patients’ paired samples.
INDELS were identified using samtools mpileup as
above, but setting the minimum fraction of gapped reads
for candidates to 0.05.
In silico spoligotyping and sub-lineage typing
Spoligotypes were generated using SpolPred [23]. Sub-
lineages were further determined using the presence or
absence of a set of 62 lineage-defining SNPs as derived
by Coll et al. [24].
Mixed infections
For each isolate sequence a count of the percentage of
reads supporting a variant base at each genome position
was plotted. Mixed isolates can be identified by the pres-
ence of an extra peak, suggesting the presence of two
genotype populations in the sequenced sample. Base
calls for the majority and minority strains were separated
based on the per cent reads and pseudo-sequences were
generated and subsequently included in the phylogenetic
reconstruction as above.
Results
Samples studied
Figure 1 shows a flowchart of the samples studied. A
total of 827 patients, with newly diagnosed, microscopy-
positive pulmonary TB were enrolled in South Africa,
Zimbabwe, Botswana and Zambia in the trial. Fifty-one
patients had positive cultures in post-treatment follow-
up and therefore required genotyping to distinguish
relapse from reinfection (as per the RIFAQUIN protocol
[17]). DNA was available to generate MIRU-VNTR data
for 44 pairs of samples (pre- and post-treatment). The
remaining DNA was passed for WGS, and good-quality
sequences (>20× coverage) were generated for both pre-
and post-treatment samples of 36 patients.
SNP differences were determined between the pairs of
isolates, and a comparison with MIRU-VNTR differ-
ences is shown in Table 1. Two main groups can be
identified: 32 pairs of isolates had five or fewer SNP
differences, and four pairs of samples had a much higher
number of SNP differences (range 737–1329). An add-
itional single pair of isolates differed by 57 SNPs, but
this was probably because the pre-treatment isolate
contained a mixed infection, as discussed below.
Phylogenetic reconstruction of SNPs
Phylogenetic reconstruction of variant SNPs (Fig. 2a)
showed that the majority (32 out of 36) of the isolate pairs
had low numbers of SNP differences and were therefore
Fig. 1 Flowchart of pairs of samples studied. MIRU mycobacterial
interspersed repetitive units, WGS whole-genome sequencing
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clearly determined as cases of relapse. One isolate pair
was identified as a mixed infection (see below). The
remaining three isolate pairs that had high numbers of
SNP differences appear quite divergent on the tree
(marked in green) and were determined as likely
reinfections.
There were also isolates that mapped closely to other pa-
tient isolates on the tree, and these merited closer attention
to see if there were genuine connections or unexpected
problems caused by possible laboratory handling errors.
Panels b and c in Fig. 2 show one class of pattern that
was observed with clustered isolate pairs, in which there
were no SNP differences between each member of a pair,
but each pair was very closely related to another pair. In
both panels, the two pairs of samples came from differ-
ent centres (panel b: 005 and 014, Harare and Marondera,
both in Zimbabwe; panel c: 008 Harare, Zimbabwe, and
001 Francistown, Botswana, on the borders of Zimbabwe;
Table 2), suggesting that a laboratory processing error was
unlikely. An alternative explanation is that highly similar
local strains were circulating in the two relatively close re-
gions and had evolved independently over time.
Panels d and e in Fig. 2 show a different type of
pattern, in which a pair of isolates from one patient
clustered together, as expected for relapses, but was also
identical to a single isolate from another pair, suggesting a
possible transmission event. In Fig. 2d, a post-treatment
sequence for isolate 009 was identical to isolate pair 012;
the two 009 isolates differed by 1233 SNPs. In Fig. 2e, a
pre-treatment isolate 004-1 was identical in sequence to
both isolates of patient 003; the two 004 isolates differed
by 737 SNPs. All four patients received treatment in the
same city, Harare (Table 2). While it is not impossible that
these genotypes were genuinely isolated from the two
patients, 009 and 004, another possible explanation is
some form of laboratory processing error. Indeed, in one
case the patients visited the hospital on the same day, and
in the other results were reported at the same time. This
combined with their geographical co-location would
further support the possible processing error interpret-
ation. It is also worth noting that if these are indeed er-
rors, they would normally be invisible to the analysis
without the resolution of WGS.
Mixed infections
One patient’s pair of samples (035) displayed 57 SNPs be-
tween the pre- (035-1) and post-treatment (035-2) isolates
and was therefore initially classified as a reinfection. How-
ever, further analysis of the WGS data showed evidence of
a mixed infection in the pre-treatment isolate (035-1;
Fig. 3a) corresponding to an approximately 75% to 25%
combination of two genotypes. Using this majority/minor-
ity ratio of read coverage, it was possible to separate the
two genotypes and further phylogenetic reconstruction
suggested that it was likely that the minority genotype
(035-1-min) was closely related to the post-treatment iso-
late (035-2; Figs. 2a and 3b). This suggests that this was in
fact a relapse of a previously unidentified minority geno-
type, rather than a reinfection as previously assigned.
Initially there appeared to be 57 SNP differences be-
tween the pre- and post-treatment isolates (035-1, 035-
2), which would have been an unusual result given that
the previous studies had only identified reinfections with
very high SNP differences, and nothing at an intermedi-
ary level. The observation of mixed genotypes would ex-
plain this discrepancy because one of the main filtering
criteria in the site-calling algorithm is to remove sites
with mixed genotype calls (<75% read support for the
call), so the real number of SNP differences between the
isolates is likely to be higher. After separating the geno-
types, it was estimated that the number of SNP differ-
ences between the pre-treatment minority genotype and
the post-treatment isolates was 869 SNPs. The pre-
treatment minority genotype and the post-treatment
isolate appeared to differ by 245 SNPs; however, the
genotype separation algorithm used was relatively crude,
with filtering based on parameter cut-offs, so it was not
possible to completely separate the genotypes at all
mixed genome sites, reflecting the overlapping shape
of the two distributions (Fig. 3a). However, the prox-
imity of their placement on the tree (Fig. 2a) suggests
they are highly related and thus this patient’s disease
was likely a relapse.
Comparing WGS with MIRU-VNTR data
Figure 4a shows there is a stark difference in the number of
SNP differences between cases of relapse and reinfection,
Table 1 Comparison between the differences in single-nucleotide
polymorphisms and mycobacterial interspersed repetitive units
SNP differences Number of isolate pairs MIRU differences
0 19 0 (n = 15)b, 1 (n = 4)
1 7 0 (n = 6)c, 2 (n = 1)
2 1 0
3 2 0
5 3 0d
57a 1 2
737 1 6
1233 1 0e
1294 1 7
MIRU mycobacterial interspersed repetitive units, SNP
single-nucleotide polymorphism
aexcluded from further SNP analysis as found to be mixed infection, but
re-interpreted as a relapse (see text)
btwo samples <10 loci [2, 7]
cone from only two informative loci
d from only five informative loci
efrom only three informative loci
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an observation also made by Bryant et al. [14]. Table 1 and
Fig. 4b show the distribution of MIRU-VNTR differences.
The majority of pairs had no MIRU-VNTR differences (out
of up to 21 loci determined), but some had a maximum of
seven loci different. We experienced technical difficulties
which meant that the number of loci amplified varied
(Table 2; see Discussion).
The relationship between SNP and MIRU-VNTR
differences is shown in Table 2 and Fig. 4c. There was a
clear MIRU-VNTR difference between those labelled as
Fig. 2 a Phylogenetic reconstruction of 36 pairs of isolates. These were inferred using 5132 high-quality single-nucleotide polymorphisms (SNPs)
following the removal of 661,083 low-quality sites and the remaining invariant sites. The tree was rooted using the H37Rv reference strain sequence.
Relapse, reinfection and mixed are denoted with black/blue, green and red tips respectively. Blue tip labels are further shown in panels b–e. b–e
Branches have been amplified where unexpected similarity was seen; the numbers of SNPs between the most divergent samples are given
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relapses using WGS (zero to two MIRU-VNTR differ-
ences) and those labelled as reinfections (seven to eight
MIRU-VNTR differences). However, within the relapse
group, there was no obvious relationship between these
two measures: all samples with two to five SNPs had no
MIRU-VNTR differences, whereas there were four with
no SNP differences and one MIRU-VNTR difference.
Overall, WGS largely agreed with MIRU-VNTR (Table 3),
with only the likely mixed infection causing a possible
discrepancy. That was based on a decision in the trial to
classify pairs with two or more MIRU-VNTR differences
as reinfections.
In silico spoligotyping and sub-lineages
Human M. tuberculosis strains have been divided into
six global lineages, and further into sub-lineages, some
of which may have distinct infection phenotypes [24]. In
addition to the whole-genome SNP-based methodology
used above, analysis using a set of 62 lineage-defining
SNPs [24] was also used to assign sub-lineages (Additional
file 1: Table S1). The three reinfections observed all in-
volved different sub-lineages in the pair (patient 004:
Euro-American LAM→ Euro-American S type; patient
009: Euro-American S-type→ East Asian; patient 015:
Euro-American T→ East Asian).
In silico spoligotyping was also performed (Additional
file 1: Table S1). Of the 32 relapse pairs, 24 had identical
spoligotypes and the remaining eight had one to seven
spacer differences; all three reinfections had different
spoligotypes (9–29 spacer differences).
Antimicrobial resistance
Drug susceptibility testing showed that only one post-
treatment isolate (004-2) had a drug-resistance pheno-
type, confirmed by genotyping (RIFR: rpoB S450L; INHR:
katG S315T; EMBR: embB M306V), while its pre-
treatment isolate partner (004-1) was susceptible to all
drugs tested. Therefore, there was no evidence of any
acquisition of antibiotic resistance during the trial in the
samples that were tested with WGS.
SNPs in relapse isolates
While most SNPs that arise in a strain between treatment
and relapse would be expected to be random, as long as
they are not deleterious, it would be a reasonable hypoth-
esis that some SNPs may actively help the bacteria survive.
Comparing the relapse pairs, 18 out of 30 SNPs were syn-
onymous and 12 out of 30 were non-synonymous
(Table 4). Of the 12 non-synonymous SNPs and two
INDELs, none were in a gene associated with antibiotic
resistance, in accord with the fact that no phenotypic re-
sistance was seen. However, two SNPs lay in genes that
are implicated in pathogenesis, both associated with esx
Type 7 secretion systems (T7SSs) [25] (discussed below).
Discussion
Relapse versus reinfection
In this study, high-quality genome sequence was gener-
ated for 36 pairs of isolates. The majority of pairs (32 of
36) were shown to have very few SNPs (≤5) between
pre- and post-treatment M. tuberculosis isolates, sug-
gestive of relapse and thus treatment failure.
On initial inspection, the other four pairs (4 of 36) had
significant SNP differences between samples (57, 737, and
two >1000), indicative of reinfection. However, phylogen-
etic analyses cast doubt on two pairs, in which a single
isolate of each pair was highly related to another patient’s
isolate in the study. While it is possible that these reflect
transmission events, it is difficult to rule out some form of
laboratory processing error; indeed, a transmission event so
similar to another pair of samples in the trial (in one case
the pre-treatment and in the other the post-treatment sam-
ples) would be relatively uncommon though not impossible,
but such a pattern would be expected if there were a sample
processing error and patient samples were swapped. A simi-
lar event was suggested by Casali et al. [26]. Indeed, trials
inserting negative samples into the TB diagnostic process
showed that errors can occur [27], but strain-typing
methods allowed actual contamination to be detected. A re-
view by Burman et al. [28] indicated a median false-positive
rate of 3.1% in published studies. WGS can thus help iden-
tify when processing errors have occurred, thereby improv-
ing overall trial data quality and acting as a quality control
measure of trial procedures.
The case with 57 SNP differences between the isolate pair
was probably a mixed infection, and while accurate SNP fig-
ures could not be obtained, the data were consistent with a
relapse from one of the two pre-existing strains. These are
described as a major/minor strain within the sequencing
data, but that may not accurately reflect the relative levels in
the patient; these levels could, for example, be affected by
colony size on the LJ slopes, and the actual loop sample
taken for DNA preparation. The isolate pair were initially
identified as being different from each other by a higher
number of SNP differences (57) than would be expected for
a relapse, but at an unusually low level of SNPs for a reinfec-
tion compared to other reported examples. This is likely to
be due to the mixed infection causing many genuine SNPs
to be discarded as uncertain by the site-calling algorithm.
Reports of similar cases of mixed infections in previous
studies [14, 15, 29] support the likelihood that this interpret-
ation may be genuine, thus suggesting that it is important to
assess isolates for evidence of mixed infections before calling
relapse/reinfection.
Therefore, from the 36 pairs of isolates sequenced, there
was strong evidence that 32 were relapses, one was a
mixed infection masking a likely relapse, and three were
reinfections, although two of these may have been the re-
sult of laboratory processing errors. This proportion (32
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of 35 (91%) relapse: 3 of 35 (9%) reinfection; excluding the
possible mixed infection) can be compared with previ-
ously reported relapse to reinfection proportions of 92:8,
also in a chemotherapy trial [14], and 73:27 in the rather
different situation of a long-term study with longer post-
treatment follow-up (over 12 years in some cases) [15].
Table 2 Relationship between single-nucleotide polymorphisms and mycobacterial interspersed repetitive units-variable number
tandem repeat differences
Study number Location Treatment arm SNPs MIRU-VNTR differences MIRU-VNTR loci amplified Prediction
001 Francistown 4 month 0 0 21 Relapse
003 Harare 4 month 0 0 14 Relapse
005 Harare 4 month 0 0 20 Relapse
007 Harare 4 month 0 0 7 Relapse
008 Harare 4 month 0 0 11 Relapse
013 Marondera 4 month 0 0 10 Relapse
014 Marondera 4 month 0 0 11 Relapse
016 Johannesburg 4 month 0 0 14 Relapse
020 Johannesburg 4 month 0 0 17 Relapse
023 Cape Town 4 month 0 0 15 Relapse
029 Cape Town 4 month 0 0 2 Relapse
030 Cape Town 4 month 0 0 15 Relapse
032 Cape Town 4 month 0 0 14 Relapse
017 Johannesburg 6 month 0 0 17 Relapse
034 Cape Town 6 month 0 0 21 Relapse
037 Cape Town Control 0 1 17 Relapse
011 Harare 4 month 0 1 16 Relapse
021 Johannesburg 4 month 0 1 16 Relapse
028 Cape Town 4 month 0 1 15 Relapse
024 Cape Town Control 1 0 18 Relapse
033 Cape Town Control 1 0 15 Relapse
010 Harare 4 month 1 0 18 Relapse
012 Harare 4 month 1 0 19 Relapse
025 Cape Town 4 month 1 0 11 Relapse
027 Cape Town 6 month 1 0 13 Relapse
019 Johannesburg Control 1 2 4 Relapse
026 Cape Town 4 month 2 0 18 Relapse
002 Harare 4 month 3 0 15 Relapse
006 Harare 4 month 3 0 12 Relapse
018 Johannesburg Control 5 0 5 Relapse
036 Cape Town 4 month 5 0 17 Relapse
031 Cape Town 6 month 5 0 16 Relapse
015 Johannesburg Control 1294 7 14 Reinfection
035 Cape Town 4 month 57a - - Relapse
004 Harare Control 737 6 6 Reinfection
009 Harare 4 month 1233 3 3 Reinfection
The 36 isolates for which whole-genome sequencing was carried out are listed. With the mixed infection, although we concluded it to be a relapse, we could not precisely
determine the SNP difference. For an explanation of the treatment arms, see the “Methods” section “RIFAQUIN trial” and Jindani et al. [17]. The table is sorted (in order) by
number of SNPs, MIRU-VNTR differences, treatment arm and study number. Isolate 004-2 had previously been shown by Drug Susceptibility Testing (DST) to be resistant to
isoniazid, rifampicin, ethambutol, streptomycin and pyrazinamide; however, all other isolates had been determined to be susceptible [17].
MIRU-VNTR mycobacterial interspersed repetitive units-variable number tandem repeats, SNP single-nucleotide polymorphisms
aIt was not possible to separate the mixed genotypes to precisely determine a SNP difference
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This latter study indicated that relapses occurred towards
the start of the follow-up, and particularly within the first
2 years, and therefore is consistent with the study reported
here.
SNP differences in this and previous studies
The number of SNP differences in the relapse and re-
infection groups was comparable to previous pre- and
post-treatment studies (Table 5). Casali et al. [26] also
found up to four SNP differences over 4 years in intra-
patient studies. In each of the previous relapse studies,
there was a large gap between the number of SNPs
found in presumed relapses and in reinfections. This
both lends support to the definition used to identify re-
lapse versus reinfection, and also gives weight to the
suggestion by Bryant et al. [14] that there is some im-
munity to reinfection by very similar strains. The same
pattern was observed in this study, even though the
phylogenetic tree showed that highly similar strains were
circulating. Guerra-Assunção et al. [15] showed less SNP
diversity in reinfections (100 rather than 1000 SNPs),
and it would be interesting to determine if there is an ef-
fect of time, with similar strains only reinfecting after a
longer passage of time. Casali et al. [26] demonstrated
that there is strain diversity within a single sputum
specimen, with up to 10 SNP differences seen when
individual colonies were sequenced. The methodology
described in this study deliberately took a sweep of col-
onies, which meant that much of this strain diversity
within a single specimen would not be seen in WGS at
the depth of coverage used.
SNPs seen in relapse isolates
For 16 of the 32 relapse pairs sequenced, SNPs were
identified between the isolates (Table 4; excluding the
mixed infection). While it is likely that many or most of
these will not be advantageous to the bacteria, it is a
plausible hypothesis that some of them might have a
survival advantage.
Of the 12 non-synonymous SNPs observed in relapse
isolate pairs, two were in gene systems that have proven
involvement with pathogenesis: the two T7SSs esx1 and
esx3. One lay in eccB3, which is a gene in the ESX3
T7SS, which is essential for growth. This system is in-
volved in pathogenesis, partly through the control of
iron acquisition, which appears to have a role in metal
homeostasis [30]. The other was located in mce1B,
which is a gene in the ESX1 T7SS, which is essential for
virulence and exports the well-characterised ESAT-6/
CFP10 complex [25]. Bryant et al. [14] reported that two
genes with SNPs had functions associated with oxidative
stress, and Guerra-Assunção et al. [15] reported an asso-
ciation with katG, well known for being involved in re-
sistance to both oxidative stress and isoniazid. Clearly
Fig. 3 Identification of mixed infection. a Counts of genome sites which were called as a reference base but showed a significant proportion of
sequence reads also supporting a variant base call (035-1); b the equivalent plot for an isolate with no mixed infection (035-2). The presence of a
second peak in a is suggestive of a mixture with a minority genotype
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these may just be chance associations, but they also indi-
cate potential avenues for studying bacterial survival
during chemotherapy. The scale of investment in phase
2 and 3 trials is such that there is an obligation to ex-
tract as much information as possible from the study
and the contribution of WGS is fundamental to under-
standing the bacteriology under treatment.
Mixed infections
A potential confounder in differentiating relapse from
reinfection is that of mixed infections. If either the
initial or subsequent infection is mixed, then sampling
just one isolate could give a misleading designation.
One likely mixed infection was identified with a 75:25
genotype ratio, although this ratio may not represent
Fig. 4 Analysis of single-nucleotide polymorphism (SNP) and mycobacterial interspersed repetitive units-variable number tandem repeat (MIRU-
VNTR) differences between pairs of isolates. Data are summarised from Tables 1 and 2. a Number of SNP differences detected between paired
isolates; b number of MIRU-VNTR differences detected between paired isolates; c correlation between SNP and MIRU differences; d number of
informative MIRU loci on which differences were based (for each pair of samples, the lower number is shown)
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the ratio of the mixture in the bacterial population in
vivo.
Of course, these methods would only reveal mixed infec-
tions with significant proportions of each strain, and it can-
not formally exclude the possibility that other infections
were also mixed, but at a very low levels. Bryant et al. [14],
Guerra-Assunção et al. [15], Casali et al. [26] and Köser et
al. [29] all identified mixed infections using WGS. Other
studies have demonstrated them using alternative tech-
niques, including MIRU-VNTR [31–34], but WGS is more
Table 4 Variants identified in relapse pairs
Strain pair Type Base numbera Gene Function
002 NS 146316 Rv0120c, fusA2 Translation
NS 345226 Rv0283, eccB3 Part of ESX-3 (essential, ESX-3 T7SS is
implicated in metal homeostasis)
S 3135592 Rv2827c-109
INDEL (TC/TCC) 3600992 Rv3224B Predicted membrane protein
006 S 1348678 Rv1205-41
S 1370403 Rv1227c
S 2828233 hisT down
010 NS 200390 Rv0170, mce1B Part of ESX-1, essential for pathogenesis
012 NS 2510502 Rv2237A CP, non-essential
017 INDEL (GC/GCC) 341124 Rv0281 Possible membrane protein
018 S 783720 fusA1
S 783729 fusA1
S 783732 fusA1
S 1476666 rrl
S 4050367 folE
019 NS 3884906 Rv3467 CHP, non-essential
024 S 848538 PPE12
025 S 1929374 Rv1703c
026 NS 1192723 Rv1069c CP, non-essential
NS 1690758 Rv1499 CHP, non-essential
027 S 114494 nrp
031 S 175753 Rv0149
S 620981 Rv0530
S 1315992 pks4
NS 1540497 Rv1367c CP, non-essential
S 2788333 plsB2
033 NS 3618159 Rv3240c, secA1 Protein export, essential
036 S 923816 lysT
NS 924229 Rvnt13, pheU tRNA
NS 924234 Rvnt13, pheU tRNA
S 924263 pheU
NS 1476973 Rvnr03, rrf 5S rRNA
Function assigned using the Tuberculist database (http://tuberculist.epfl.ch/)
aSNPs between individual pairs predicted to be relapse
CHP conserved hypothetical protein, CP conserved protein, NS non-synonymous SNP, S synonymous SNP, SNP single-nucleotide polymorphism
Table 3 Comparison of the use of whole-genome sequencing
with mycobacterial interspersed repetitive units-variable number
tandem repeats for calling relapse or reinfection
MIRU-VNTR WGS
Relapse 32 33
Reinfection 4 3
MIRU mycobacterial interspersed repetitive units-variable number tandem
repeats, WGS whole-genome sequencing
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powerful, and Bryant et al. [14] found that WGS detected
more mixed infections than MIRU-VNTR.
The definition of a mixed infection is made less clear by
the finding that at least 10 SNP differences can be found
within a single sputum sample [26], and the observation
that very similar strains circulate in high-prevalence
settings (e.g. Fig. 2). However, the data here and in the
previous relapse studies [14] suggest that some sort of im-
munological protection might exist that makes successful
co-infection with a similar strain less likely.
Comparing WGS to MIRU-VNTR and spoligotyping
Previously, owing to its speed and digital output, MIRU-
VNTR has been preferred to the earlier IS6110 profiling
as a means of typing M. tuberculosis isolates; indeed, it
was only recently described as “the new reference stand-
ard for molecular epidemiological studies” [35].
In this study, there was a correlation between SNP and
MIRU-VNTR differences for isolates predicted to be
cases of relapse (0–5 SNP; 0–2 MIRU-VNTR loci) and
reinfection (SNP > 1000; MIRU-VNTR loci ≥7). This is
in contrast with the study of Bryant et al. [14] who re-
ported that three reinfection pairs had 1–13 different
loci, although that study was an interim analysis per-
formed prior to final data resolution and unbinding,
which may have impacted on the ultimate assignment of
the patients. Furthermore, Casali et al. [26] found that
two MIRU-VNTR differences could correspond to a sig-
nificant number of SNP differences. A transmission study
by Walker et al. [11] only examined isolates with success-
ful 24-loci MIRU-VNTR data, showing that, up to a differ-
ence of 100 SNPs, isolates could have 1–3 MIRU-VNTR
locus differences, while above 100 SNP differences, the
number of MIRU-VNTR changes increased.
Achieving consistent results with MIRU-VNTR, which
involves 24 multiplexed PCRs, is known to be technically
challenging [14, 26, 36, 37]. Indeed, there was significant
variation in the number of loci amplified in this study
(Table 2, Fig. 4d), which we attribute to a combination
of DNA quantity and quality, and the technical difficul-
ties referred to above. Furthermore, other limitations
and issues with MIRU-VNTR in relation to the study
setting have been discussed in a systematic review [38].
WGS is technically more straightforward and was
comparable in cost in our hands (~£100 per sample),
but with reducing costs and whole-genome resolution, it
is clearly a superior, more robust method then MIRU-
VNTR for strain typing. In addition, WGS can provide
additional information by identifying markers associated
with drug resistance, which could be useful in the con-
text of relapsing cases in a clinical trial. Sequence data is
also more amenable to incorporation into other studies
and will provide further information on TB evolution as
global databases of genome information grow.
Spoligotyping has been widely used for robust division
of M. tuberculosis into different sub-types [4], but we
found that SNPs were not only far more sensitive for de-
termining relapses and reinfections, but also more useful
for assigning sub-lineages.
Value of WGS in chemotherapy trials
The data from this study in combination with the previous
two relapse studies [14, 15] allow an evaluation of the relative
benefit of using WGS or MIRU-VNTR as a means of deter-
mining relapses from reinfections in chemotherapy trials.
The RIFAQUIN trial was in an area of high endem-
icity, suggesting that reinfections are not likely to be
higher elsewhere due to disease prevalence. Thus, the
data presented in this study and previously [14, 15] indi-
cate that the proportion of reinfections is very low com-
pared to relapse, although Guerra-Assunção et al. [15]
suggest that reinfections may rise at later time points
after completion of therapy. Furthermore, cases in which
isolates are identified as reinfections are more likely to
be wrong, because the possible errors observed here
(processing errors, unrecognized mixed infections) are
more likely to suggest a reinfection.
Conclusions
In the pre-genomic era, all post-treatment infections were
presumed to be relapses, and it could be argued that, due
to the low reinfection rates and the increased cost and
time required to perform the sequencing, WGS provides
only modest gains for the analysis of the primary outcome
in a chemotherapy clinical trial of this nature.
Nevertheless, in addition to robust genomic evidence
for treatment outcome, the added information that WGS
provides is scientifically valuable and will become of
greater value as more genome sequence data and more in-
formation about the genotype–phenotype correlation and
its impact on disease and transmission becomes available.
Furthermore, future trials for new TB drugs in the devel-
opment pipeline or novel combination regimens may be
held in areas of high TB prevalence where re-infection or
mixed infections are more likely, thus making accurate
strain discrimination imperative; in these instances, WGS
should be the method of choice.
Table 5 Number of single-nucleotide polymorphism differences
between relapse and reinfection paired samples in different
studies
Relapse
group
Reinfection
group
Maximum length
of follow-up
Study
0–5 >1000 18 months This study
0–6 >1300 18 months Bryant et al. [14]
0–8 >100 >12 years Guerra-Assunção et al. [15]
Witney et al. BMC Medicine  (2017) 15:71 Page 11 of 13
Additional file
Additional file 1: Table S1. Spoligotype and sub-lineage information
for isolates. (DOCX 23 kb)
Acknowledgements
MIRU-VNTR analyses were carried out by Selina Bannoo, Emma Cunningham,
Alice Morgan, Solomon Mwaigwishya and Laura Wright. Sequencing was
carried out at UCL Genomics by Tony Brooks and Nipurna Jina.
Funding
The RIFAQUIN trial was funded by the European and Developing Countries
Clinical Trials Partnership and the Wellcome Trust; RIFAQUIN Current
Controlled Trials number, ISRCTN44153044.
Availability of data and materials
Sequence data has been submitted to the ENA database with accession
number PRJEB18529. The full analysis pipeline can be downloaded and run
from http://github.com/bugs-bioinf/rifaquin-2016.
Authors’ contributions
AW, AB, PP and NS performed the data analysis; DC cultured the isolates; AJ,
PB and TM designed the study. All authors contributed to the writing of the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol was reviewed and approved by the ethics review committee
at St. George’s by medical ethics and regulatory committees representing each
of the participating countries, and by the institutional review board of the
Centers for Disease Control and Prevention operating in Botswana.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute for Infection and Immunity, St George’s University of London,
London, UK. 2UCL Centre for Clinical Microbiology, Royal Free Campus, UCL,
London, UK. 3MRC Clinical Trials Unit at UCL, London, UK.
Received: 13 December 2016 Accepted: 9 March 2017
References
1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis
undertaken by the British Medical Research Council tuberculosis units, 1946-
1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;
3(10 Suppl 2):S231–279.
2. Hermans PW, van Soolingen D, Dale JW, Schuitema AR, McAdam RA, Catty D,
et al. Insertion element IS986 from Mycobacterium tuberculosis: a useful tool
for diagnosis and epidemiology of tuberculosis. J Clin Microbiol. 1990;28(9):
2051–8.
3. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E,
et al. Proposal for standardization of optimized mycobacterial interspersed
repetitive unit-variable-number tandem repeat typing of Mycobacterium
tuberculosis. J Clin Microbiol. 2006;44(12):4498–510.
4. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et
al. Simultaneous detection and strain differentiation of Mycobacterium
tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35(4):907–14.
5. Das S, Chan SL, Allen BW, Mitchison DA, Lowrie DB. Application of DNA
fingerprinting with IS986 to sequential mycobacterial isolates obtained from
pulmonary tuberculosis patients in Hong Kong before, during and after
short-course chemotherapy. Tuber Lung Dis. 1993;74(1):47–51.
6. Tam CM, Chan SL, Kam KM, Sim E, Staples D, Sole KM, et al. Rifapentine and
isoniazid in the continuation phase of a 6-month regimen. Interim report:
no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis.
2000;4(3):262–7.
7. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al.
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a
week for treatment of drug-susceptible pulmonary tuberculosis in HIV-
negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528–34.
8. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, et al.
Efficacy and safety of a 4-drug fixed-dose combination regimen compared
with separate drugs for treatment of pulmonary tuberculosis: the Study C
randomized controlled trial. JAMA. 2011;305(14):1415–23.
9. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy
for treatment of newly diagnosed pulmonary tuberculosis: international
multicentre randomised trial. Lancet. 2004;364(9441):1244–51.
10. Walker TM, Monk P, Grace Smith E, Peto TEA. Contact investigations for
outbreaks of Mycobacterium tuberculosis: advances through whole
genome sequencing. Clin Microbiol Infect. 2013;19(9):796–802.
11. Walker TM, Lalor MK, Broda A, Saldana Ortega L, Morgan M, Parker L, et al.
Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK,
2007-12, with whole pathogen genome sequences: an observational study.
Lancet Respir Med. 2014;2(4):285–92.
12. Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, et al. Whole-
genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a
retrospective observational study. Lancet Infect Dis. 2013;13(2):137–46.
13. Satta G, Witney AA, Shorten RJ, Karlikowska M, Lipman M, McHugh TD.
Genetic variation in Mycobacterium tuberculosis isolates from a London
outbreak associated with isoniazid resistance. BMC Med. 2016;14(1):117.
14. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH, van Helden P, et al.
Whole-genome sequencing to establish relapse or re-infection with
Mycobacterium tuberculosis: a retrospective observational study. Lancet
Respir Med. 2013;1(10):786–92.
15. Guerra-Assunção J, Crampin A, Houben R, Mzembe T, Mallard K, Coll F, et al.
Large-scale whole genome sequencing of M. tuberculosis provides insights into
transmission in a high prevalence area. eLife. 2015. doi: 10.7554/eLife.05166
16. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al.
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N
Engl J Med. 2014;371(17):1577–87.
17. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous
S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
N Engl J Med. 2014;371(17):1599–608.
18. Kent L, McHugh TD, Billington O, Dale JW, Gillespie SH. Demonstration of
homology between IS6110 of Mycobacterium tuberculosis and DNAs of
other Mycobacterium spp.? J Clin Microbiol. 1995;33(9):2290–3.
19. Kozarewa I, Turner DJ. 96-plex molecular barcoding for the Illumina
Genome Analyzer. Methods Mol Biol Clifton NJ. 2011;733:279–98.
20. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-
MEM. ArXiv13033997 Q-Bio. 2013. http://arxiv.org/abs/1303.3997. Cited 7 July 2014.
21. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
22. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-
analysis of large phylogenies. Bioinformatics. 2014;30(9):1312–3.
23. Coll F, Mallard K, Preston MD, Bentley S, Parkhill J, McNerney R, et al. SpolPred:
rapid and accurate prediction of Mycobacterium tuberculosis spoligotypes
from short genomic sequences. Bioinformatics. 2012;28(22):2991–3.
24. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, et al.
A robust SNP barcode for typing Mycobacterium tuberculosis complex strains.
Nat Commun. 2014;5:4812.
25. Majlessi L, Prados-Rosales R, Casadevall A, Brosch R. Release of
mycobacterial antigens. Immunol Rev. 2015;264(1):25–45.
26. Casali N, Broda A, Harris SR, Parkhill J, Brown T, Drobniewski F. Whole
genome sequence analysis of a large isoniazid-resistant tuberculosis
outbreak in London: a retrospective observational study. PLoS Med. 2016;
13(10):e1002137.
27. Aber VR, Allen BW, Mitchison DA, Ayuma P, Edwards EA, Keyes AB. Quality
control in tuberculosis bacteriology. 1. Laboratory studies on isolated
positive cultures and the efficiency of direct smear examination. Tubercle.
1980;61(3):123–33.
28. Burman WJ, Reves RR. Review of false-positive cultures for Mycobacterium
tuberculosis and recommendations for avoiding unnecessary treatment.
Clin Infect Dis. 2000;31(6):1390–5.
Witney et al. BMC Medicine  (2017) 15:71 Page 12 of 13
29. Köser C, Bryant JM, Becq J, Torok ME, Ellington MJ, Marti-Renom MA, et al.
Whole-genome sequencing for rapid susceptibility testing of M.
tuberculosis. N Engl J Med. 2013;369(3):290–2.
30. Tufariello JM, Chapman JR, Kerantzas CA, Wong K-W, Vilchèze C, Jones CM,
et al. Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron
acquisition and virulence. Proc Natl Acad Sci. 2016;113(3):E348–57.
31. Hanekom M, Streicher EM, de Berg DV, Cox H, McDermid C, Bosman M, et al.
Population structure of mixed Mycobacterium tuberculosis infection is strain
genotype and culture medium dependent. PLoS One. 2013;8(7):e70178.
32. Fang R, Li X, Li J, Wu J, Shen X, Gui X, et al. Mixed infections of
Mycobacterium tuberculosis in tuberculosis patients in Shanghai, China.
Ann Tuberc. 2008;88(5):469–73.
33. Mallard K, McNerney R, Crampin AC, Houben R, Ndlovu R, Munthali L, et al.
Molecular detection of mixed infections of Mycobacterium tuberculosis
strains in sputum samples from patients in Karonga District, Malawi.
J Clin Microbiol. 2010;48(12):4512–8.
34. Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M. Mixed-strain
Mycobacterium tuberculosis infections among patients dying in a hospital
in KwaZulu-Natal, South Africa. J Clin Microbiol. 2011;49(1):385–8.
35. Brossier F, Sola C, Millot G, Jarlier V, Veziris N, Sougakoff W. Comparison of a
semiautomated commercial repetitive-sequence-based PCR method with
spoligotyping, 24-locus mycobacterial interspersed repetitive-unit-variable-
number tandem-repeat typing, and restriction fragment length
polymorphism-based analysis of IS6110 for Mycobacterium tuberculosis
typing. J Clin Microbiol. 2014;52(11):4082–6.
36. Cowan LS, Mosher L, Diem L, Massey JP, Crawford JT. Variable-number
tandem repeat typing of Mycobacterium tuberculosis isolates with low
copy numbers of IS6110 by using mycobacterial interspersed repetitive
units. J Clin Microbiol. 2002;40(5):1592–602.
37. Chatterjee A, Mistry N. MIRU–VNTR profiles of three major Mycobacterium
tuberculosis spoligotypes found in western India. Tuberculosis. 2013;93(2):250–6.
38. Mears J, Abubakar I, Cohen T, McHugh TD, Sonnenberg P. Effect of study
design and setting on tuberculosis clustering estimates using mycobacterial
interspersed repetitive units-variable number tandem repeats (MIRU-VNTR):
a systematic review. BMJ Open. 2015;5(1):e005636.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Witney et al. BMC Medicine  (2017) 15:71 Page 13 of 13
